tirzepatide
How a GLP-1 ‘Shadow System’ Puts Patients’ Safety at Risk
Dozens of unscrupulous web-based sellers of glucagon-like peptide-1 agonist drugs are evading FDA scrutiny and ...
NOVEMBER 7, 2024
Study Finds GLP-1s Safe and Effective For Managing Obesity in Patients With IBD
GLP-1s are well tolerated and effective for weight loss in patients with IBD, according to new research
NOVEMBER 6, 2024
'A War Brewing’ Between GLP-1 Manufacturers and Compounders
Are glucagon-like peptide-1 drugs like semaglutide and tirzepatide too complex for 503A and 503B compounders to ...
NOVEMBER 1, 2024
'Tail Period' for Compounders Could Ease Weight-Loss Rx Shortages
Compounder should be allowed to produce products beyond the FDA’s current hard compounding cut-off. The ...
OCTOBER 10, 2024
Dangerous Market for Weight-Loss Drugs Grows Online
High demand and short supply of GLP-1 antagonists used to treat diabetes and obesity have led many people desperate ...
DECEMBER 19, 2023
FDA Approves Dual-Targeted Treatment for Type 2 Diabetes
The FDA approved tirzepatide (Mounjaro, Eli Lilly) as an adjunct therapy to diet and exercise for improving ...
MAY 13, 2022
